Stockholm Plant, Sweden
Located at Lake Mälaren in the west of Stockholm and originally owned by Kabi (later Pharmacia, and then spin-off Biovitrum), the site has been involved in plasma fractionation since the 1940s. The first plasma protein, albumin, was supplied to the market in 1949 followed by gamma globulin in 1950. Additionally, in the mid-1960s, Kabi was one of the two first commercial companies in the world to introduce a Factor VIII concentrate.
Octapharma acquired the plant, which was the Plasma Products Division of Biovitrum, in July 2002. The production facilities were subsequently converted to enable the continuous production of both Biovitrum’s existing plasma products as well as Octapharma’s product range.
Ongoing investments into the acquisition and adaptation of expanded premises, such as the adjacent historic brewery building, as well as installation of state-of the art production equipment, increased the plant’s annual capacity from 300,000 litres in 2002 to 1.3 million litres in 2012. In addition, new laboratories and office facilities were opened to provide optimal working conditions for a staff of over 575 people.
In 2003, the pharmaceutical development of Octapharma's recombinant Factor VIII was transferred from basic research at Octapharma Biopharmaceuticals GmbH, Munich, to the Stockholm development and pilot plants.
Quality & safety
The plant’s Quality System, which already held an FDA license, has been harmonised with the Octapharma system. This facilitated the rapid granting of FDA licenses for octagam® and albumin in 2006 and 2008 respectively, making the Stockholm plant a valuable contributor in supplying the US market.
Fractionation/purification; pharmaceutical production; labelling, packaging and storage facilities; Quality Control laboratories; PCR testing; pilot plant and full-scale production plant for recombinant factor VIII; administrative units.
Octapharma OAB (Operations)
Octapharma Nordic (Marketing & Sales)
octagam®, albunormTM, octanate®, octaplas®, nanotiv®, gammanorm®, atenativ®, rhesonativ®, recombinant Factor VIII
Annual plasma fractionation capacity
1.3 million litres
“One of the keys to our performance is the commitment of our staff. We place a high level of trust in our teams at every level of the organisation.”